头颈癌治疗前神经认知损害与言语功能评估
该前瞻性队列研究在荷兰全国多中心纳入254例新诊断头颈癌患者,于治疗前评估客观神经认知、患者报告的神经认知与言语功能。结果显示客观认知损害患病率4.7%至15.0%,言语问题报告率42.6%;客观认知功能与患者报告结局无显著关联,患者报告指标间显著相关。
要点
- 头颈癌治疗前客观神经认知中重度损害患病率为4.7%至15.0%,轻度至中度损害为12.3%至26.2%。
- 治疗前42.6%的患者报告存在言语问题,7%报告高水平日常神经认知失败。
- 客观神经认知功能与患者报告的神经认知或言语功能无显著关联,患者报告结局指标间显著相关。
核心结论
- 头颈癌患者治疗前言语功能损害患病率高,客观测量和自报告的神经认知损害亦均高发。
- 治疗前神经认知损害可能影响医患沟通、治疗依从性,且治疗本身可能进一步恶化认知功能。
- 厘清客观与患者报告的神经认知及言语功能之间的关联是未来研究的重要方向。
研究设计与样本
- 前瞻性队列研究,使用荷兰全国多中心头颈癌生活质量与生物医学队列研究(NET-QUBIC)项目的大型样本。
- 纳入254例新诊断头颈癌治疗前患者,男性占71.7%,平均(标准差)年龄62(10)岁。
- 应答率范围为81.9%(208/254)至84.6%(215/254)。
主要发现
- 客观神经认知测量显示,4.7%(10/212)至15.0%(32/214)的患者初诊时存在中度至重度认知损害,12.3%(26/212)至26.2%(56/214)存在轻度至中度损害。
- 最常受累的认知域为延迟回忆和字母流畅性。
- 7%(15/208)的患者报告高水平日常神经认知失败,42.6%(89/209)报告言语问题。
- 客观神经认知功能与患者报告的神经认知或言语功能无显著关联,但患者报告结局指标之间显著相关。
关键数值与推荐
- 客观认知损害:中重度4.7%(10/212)至15.0%(32/214),轻度至中度12.3%(26/212)至26.2%(56/214)。
- 患者报告:高水平日常神经认知失败7%(15/208),言语问题42.6%(89/209)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需厘清客观与患者报告的神经认知及言语功能之间的关联,是未来研究的重要领域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Head and neck cancer (HNC) and its treatment may negatively alter neurocognitive and speech functioning. However, the prevalence of neurocognitive impairment among patients with HNC before treatment is poorly studied, and the association between neurocognitive and speech functioning is unknown, which hampers good interpretability of the effect of HNC treatment on neurocognitive and speech function. OBJECTIVES: To document neurocognitive functioning in patients with HNC before treatment and to investigate the association between neurocognitive and speech functioning. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of newly diagnosed patients with HNC before treatment using a large sample obtained in a nationwide, multicenter setting (Netherlands Quality of Life and Biomedical Cohort Study in Head and Neck Cancer [NET-QUBIC] project). MAIN OUTCOME AND MEASURES: Objective neuropsychological measures of delayed recall, letter fluency, and executive functioning, as well as patient-reported outcome measures on neurocognitive speech and functioning, were collected before treatment. RESULTS: In total, 254 patients with HNC participated (71.7% male), with a mean (SD) age of 62 (10) years. The response rate ranged from 81.9% (208 of 254) to 84.6% (215 of 254). Objective neurocognitive measures indicated that 4.7% (10 of 212) to 15.0% (32 of 214) of patients were initially seen with moderate to severe cognitive impairment. Mild to moderate impairment was found in 12.3% (26 of 212) to 26.2% (56 of 214) of patients. The most altered domains were delayed recall and letter fluency. Seven percent (15 of 208) of the patients reported high levels of everyday neurocognitive failure, and 42.6% (89 of 209) reported speech problems. Objective neurocognitive function was not significantly associated with patient-reported neurocognitive or speech functioning, but the results from patient-reported outcome measures were significantly correlated. CONCLUSIONS AND RELEVANCE: Results of this study demonstrate a high prevalence of impaired speech functioning among patients with HNC before treatment, which is in line with previous findings. A novel finding is that neurocognitive impairment is also highly prevalent as objectively measured and as self-perceived. Understanding the reason why patients with HNC are initially seen with neurocognitive impairment before the start of treatment is important because this impairment may complicate patient-clinician interaction and alter treatment adherence and because treatment itself may further worsen cognitive functioning. In addition, low self-perceived neurocognitive and speech functioning before treatment may decrease a patient's confidence in communicative participation and perceived quality of life. Disentangling the associations between objective and patient-reported neurocognitive and speech functions is an important area for future research.
引用
- Piai V, Prins JB, Verdonck-de Leeuw IM, et al. Assessment of Neurocognitive Impairment and Speech Functioning Before Head and Neck Cancer Treatment. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30676629. doi:10.1001/jamaoto.2018.3981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。